Emerging therapeutic agents for lung cancer | Journal of Hematology & Oncology | Full Text
Complications following novel therapies for non‐small cell lung cancer - Skribek - 2022 - Journal of Internal Medicine - Wiley Online Library
Amivantamab mechanisms of action | Download Scientific Diagram
Dual inhibition of Akt and c‐Met as a second‐line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells - Han - 2017 - Molecular Oncology - Wiley Online Library
Frontiers | Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
A New Type of Recyclable: Finding New Uses for Established Drugs｜Tokyo Medical and Dental University, National University Corporation
Frontiers | HGF/c-Met Axis: The Advanced Development in Digestive System Cancer
Cancers | Free Full-Text | Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment
Kinase Inhibitors and Atrial Fibrillation: Mechanisms of Action and Clinical Implications | JACC: Clinical Electrophysiology
Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer - Lingzhi Hong, Jianjun Zhang, John V. Heymach, Xiuning Le, 2021
The METeoric rise of MET in lung cancer - Friedlaender - 2020 - Cancer - Wiley Online Library
JPM | Free Full-Text | MET Gene Dysregulation as a Promising Therapeutic Target in Lung Cancer—A Review
Capmatinib (INCB28060) | 99.99%(HPLC) | Selleck | c-Met inhibitor
Safety and Tolerability of c-MET Inhibitors in Cancer. - Abstract - Europe PMC
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies - Cancer Treatment Reviews
Frontiers | Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
New Drug Product: Tabrecta - MPR
The role of MET in chemotherapy resistance | Oncogene
The c-Met inhibitor capmatinib alleviates acetaminophen-induced hepatotoxicity | Request PDF
Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer. - Abstract - Europe PMC
Amivantamab: A Potent Novel EGFR/c-MET Bispecific Antibody Therapy for EGFR-mutated Non-small Cell Lung Cancer - touchONCOLOGY
![PDF] Acquired resistance mechanisms to capmatinib, a MET inhibitor in MET-amplified non-small cell lung cancer cells | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/479267b462183671c1f9b52b4758ff507a880a2e/43-Figure11-1.png "PDF] Acquired resistance mechanisms to capmatinib, a MET inhibitor in MET-amplified non-small cell lung cancer cells | Semantic Scholar")
PDF] Acquired resistance mechanisms to capmatinib, a MET inhibitor in MET-amplified non-small cell lung cancer cells | Semantic Scholar
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
